Jiangsu Hengrui Medicine and TG Therapeutics’ Global License Agreement for Development and Commercialization of Novel BTK Inhibitor Program

Goodwin advised Jiangsu Hengrui Medicine as it entered into an exclusive global license agreement with TG Therapeutics.

Under the terms of the agreement, Jiangsu Hengrui will receive an up-front licensing fee and near-term milestones, payable in TG common stock, and will be eligible to receive additional payments contingent on certain clinical, regulatory and commercial milestones, totaling approximately $350 million, as well as tiered royalties on net sales.

Jiangsu Hengrui Medicine is a leading biopharmaceutical company based in China with annual net sales of over $1.6 billion in 2016. The company, led by Yun Shu Zhou, Zhou Song, Guo Qing Cao, Hong Bin Dai and Su Mei Jiang, is based in Lianyungang.

The Goodwin team was led by partner Christopher Denn (Picture) and included partner Qing Nian.

Involved fees earner: Christopher Denn – Goodwin Procter; Qing Nian – Goodwin Procter;

Law Firms: Goodwin Procter;

Clients: Jiangsu Hengrui Medicine Co., Ltd.;


Author: Ambrogio Visconti